The United States Food and Drug Administration (FDA) is currently seeking public comment regarding the potential rescheduling of marijuana and 16 other substances.
“The Food and Drug Administration (FDA) is requesting interested persons to submit comments concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use of” cannabis and 16 other substances, says Leslie Kux, FDA’s Associate Commissioner for Policy, in a Federal Register posting.
“These comments will be considered in preparing a response from the United States to the World Health Organization (WHO) regarding the abuse liability and diversion of these drugs. WHO will use this information to consider whether to recommend that certain international restrictions be placed on these drugs.”
The WHO’s Expert Committee on Drug Dependence (ECDD) is meeting next month to consider the classification of not just marijuana, but a list of other substances.
Kux notes that “This notice requesting comments is required by the Controlled Substances Act (the CSA).”
According to the Federal Register posting:
“You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before (enter date), 2018. The https://www.regulations.gov electronic filing